Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 209 full-time employees. The company went IPO on 2013-08-08. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. Its lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. AG019 ActoBiotics is a disease-modifying approach to induce antigen-specific immune tolerance to prevent, delay or reverse type-1 diabetes (T1D).